Premium
Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy
Author(s) -
Hoffmann Ingrid M.,
Rubin Bruce K.,
Iskandar Samy S.,
Schechter Michael S.,
Nagaraj Shashi K.,
Bitzan Martin M.
Publication year - 2002
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.10185
Subject(s) - medicine , tobramycin , cystic fibrosis , aminoglycoside , dosing , antibiotics , intensive care medicine , gentamicin , microbiology and biotechnology , biology
We describe a 20‐year‐old patient with cystic fibrosis who developed acute nonoliguric renal failure associated with inhaled tobramycin. Clinical evaluation and renal biopsy findings were consistent with aminoglycoside‐induced changes. Renal failure due to inhaled aminoglycosides has not been previously reported. The incidence may rise, however, with the increased use of this treatment modality. Measurable tobramycin levels due to inhalational therapy with conventional dosing in the reported patient indicate that the drug can be systemically absorbed, and renal tubular toxicity may occur. Pediatr Pulmonol. 2002; 34:375–377. © 2002 Wiley‐Liss, Inc.